Category NRXP

NRx Pharmaceuticals has become a far more layered story than the version many traders were following a few months ago. It is no longer just an abstract ketamine thesis or a speculative real-world-evidence talking point. As of April 20, 2026, the company has three separate but connected tracks worth watching: a near-term generic-drug approval set-up through KETAFREE™, a potentially more valuable but still higher-risk NDA strategy for NRX-100, and an expanding clinic / neurotechnology ecosystem designed to create commercial infrastructure around both drug assets.

NRx Pharmaceuticals finally got the kind of news biotech traders usually wait for: not just another optimistic corporate interpretation, but formal written FDA minutes that document the regulatory path. In today’s release, the company said it received the confirmatory written minutes from its February 17, 2026 in-person Type C meeting with the FDA. According to NRx, those minutes support a path to file an NDA for NRX-100 by June 2026 using existing adequate and well-controlled clinical trial data together with confirmatory Real World Evidence. The company also said the FDA confirmed that no additional clinical trials and no bridging studies are required for the preservative-free formulation

NRx Pharmaceuticals is a micro-cap biotech focused on severe psychiatric conditions: suicidal depression, bipolar depression with suicidality, PTSD and related disorders. The core of the story is NRX-100, a preservative-free intravenous ketamine program supported by a large Real-World Evidence dataset, and NRX-101, an oral D-cycloserine + lurasidone combination with Breakthrough designation. Around those assets, the company is building HOPE Therapeutics, a network of interventional psychiatry clinics that should both validate the care model and generate revenue.

NRx has licensed a nationwide Real-World Evidence dataset from Osmind covering more than 70,000 patients treated with IV ketamine or intranasal esketamine for major depression with suicidal ideation. The full analysis will be submitted to the FDA in support of an Accelerated Approval application for NRX-100, the preservative-free ketamine IV formulation already under Fast Track Designation for suicidal ideation in depression and bipolar depression.

Over the last 18–24 months, NRx Pharmaceuticals (NRXP) has built a storyline around NRX-100 (preservative-free IV ketamine) that many retail traders translated into a simple, crisp line: “PDUFA by year-end 2025.”